Skip to main content
Premium Trial:

Request an Annual Quote

Hilde Furberg, Guido Oelkers

Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Hilde has previously worked at companies including Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.

In addition, Blueprint has appointed Guido Oelkers as a senior advisor to the firm. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. Previously, he served in roles including CEO of BSN Medical, CEO of Gambro, CEO of Invida, and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis. 

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.